Active Biotech's Prostate Cancer Project TASQ in Phase I Combination Therapy Trial

25-Jan-2012 - A Phase I Investigator sponsored clinical trial, led by Principal Investigator Dr. Andrew Armstrong at Duke University Hospital, US, has been announced for Active Biotech's prostate cancer project TASQ. The primary objective for the CATCH trial (Cabazitaxel (Jevtana) And Tasquinimod in Men with ...

Investigational Laquinimod demonstrates its potential as a new oral treatment for RRMS

21-Oct-2011 - Teva Pharmaceutical Industries Ltd. and Active Biotech announced the presentation of Phase III clinical and pre-clinical data, which collectively demonstrate that once-daily oral laquinimod modulates the pathological processes of multiple sclerosis to impact disease activity, disability ...

Results of Phase III Bravo trial reinforce unique profile of laquinimod for multiple sclerosis treatment

Primary endpoint of reducing annualized relapse rate was not statistically achieved

02-Aug-2011 - Teva Pharmaceutical Industries Ltd. and Active Biotech announced initial results from the Phase III BRAVO study, which was designed to evaluate the efficacy, safety and tolerability of oral laquinimod compared to placebo and to provide a benefit-risk assessment comparing oral laquinimod and a ...

Evotec and Active Biotech Enter into Medicinal Chemistry Collaboration

09-Jun-2011 - Evotec AG announced that it has entered into a medicinal chemistry collaboration with Active Biotech AB, following the successful conclusion of a High Throughput Screening campaign to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in ...

Active Biotech's nomination committee proposes election of an additional new board member

15-Apr-2011 - Active Biotech's nomination committee has proposed that the annual general meeting on 5 May 2011 re-elect Mats Arnhög, Klas Kärre, Magnhild Sandberg-Wollheim and Peter Sjöstrand as board members and that Peter Hofvenstam and Peter Thelin be elected new members of the board.The nomination ...

Helén Tuvesson appointed as new Chief Scientific Officer at Active Biotech

16-Mar-2011 - Dr. Helén Tuvesson takes up the post as Chief Scientific Officer within Active Biotech from April 1, 2011. Helén Tuvesson will be reporting to Tomas Leanderson, President & CEO.Dr. Tuvesson has worked in the pharmaceutical industry for more than 20 years and has extensive experience in drug ...

Teva announces successful results of Phase III with oral laquinimod for multiple sclerosis

10-Dec-2010 - Teva Pharmaceutical Industries Ltd. and Active Biotech announced initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in ...

Evotec Signs High Throughput Screening Agreement with Active Biotech

15-Mar-2010 - Evotec AG announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer. Evotec will use its expertise and technologies in assay development, ...

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial in prostate cancer patients

16-Dec-2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's ongoing Phase II clinical study of TASQ, in patients with asymptomatic, castrate resistant, metastatic prostate cancer. In this ...

Tomas Leanderson appointed new President & CEO for Active Biotech

25-Jul-2008 - Sven Andréasson has notified the Board of his wish to resign from the position as President & CEO of Active Biotech AB. Sven Andréasson has been the company's CEO since 1999 and under his leadership Active Biotech has been transformed from a combined vaccine and research company into a company ...